Aadi Bioscience (NASDAQ:AADI) Price Target Cut to $47.00 by Analysts at LADENBURG THALM/SH SH

Aadi Bioscience (NASDAQ:AADIGet Rating) had its price objective trimmed by LADENBURG THALM/SH SH to $47.00 in a report released on Tuesday morning, Stock Target Advisor reports.

Aadi Bioscience Trading Up 1.6 %

Shares of Aadi Bioscience stock opened at $13.41 on Tuesday. Aadi Bioscience has a 12-month low of $11.00 and a 12-month high of $32.50. The company has a market cap of $327.14 million, a price-to-earnings ratio of -4.50 and a beta of 1.28. The company’s 50-day moving average price is $13.03 and its 200-day moving average price is $13.44.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Legal & General Group Plc purchased a new stake in Aadi Bioscience in the second quarter worth $34,000. Strs Ohio bought a new stake in Aadi Bioscience in the 2nd quarter worth about $41,000. Royal Bank of Canada bought a new stake in Aadi Bioscience in the 1st quarter worth about $49,000. American International Group Inc. bought a new stake in Aadi Bioscience in the 2nd quarter worth about $83,000. Finally, Tower Research Capital LLC TRC increased its holdings in Aadi Bioscience by 59.4% in the 3rd quarter. Tower Research Capital LLC TRC now owns 6,462 shares of the company’s stock worth $91,000 after buying an additional 2,408 shares in the last quarter. 63.00% of the stock is currently owned by institutional investors.

Aadi Bioscience Company Profile

(Get Rating)

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.

Featured Stories

Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.